NasdaqCM - Nasdaq Real Time Price USD

Jaguar Health, Inc. (JAGX)

Compare

0.9693

-0.0058

(-0.59%)

At close: December 13 at 4:00:02 PM EST

0.9380

-0.03

(-3.23%)

After hours: 7:59:27 PM EST

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal ...

ACCESSWIRE 17 hours ago

JAGX
-0.59%
Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today provided an overview of the data from the poster presentation conducted yesterday, December 11, 2024, at the San Antonio Breast Cancer Symposium (SABCS) ...

ACCESSWIRE yesterday

JAGX
-0.59%
Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the data from the recently conducted analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, ...

ACCESSWIRE 4 days ago

JAGX
-0.59%
U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, ...

ACCESSWIRE 7 days ago

JAGX
-0.59%
Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that an article about Canalevia-CA1 (crofelemer delayed-release tablets), Jaguar's prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, has been published in ...

ACCESSWIRE 8 days ago

JAGX
-0.59%
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 9 days ago

UCAR

OPWEF

BIXT
Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today issued a reminder that company personnel are attending the Pet Connect conference, taking place December 3-5, 2024 in Los Angeles, ...

ACCESSWIRE 11 days ago

JAGX
-0.59%
Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

SAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 /Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth ...

ACCESSWIRE 18 days ago

JAGX
-0.59%
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Canalevia®-CA1, ...

ACCESSWIRE 21 days ago

JAGX
-0.59%
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2024 /Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics has been named "Best Pharmaceuticals Innovator of the Year - Europe" by The European, a quarterly ...

ACCESSWIRE 24 days ago

JAGX
-0.59%
Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Jaguar Health ( NASDAQ:JAGX ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.11m (up 11% from 3Q 2023...

Simply Wall St. 27 days ago

JAGX
-0.59%
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Jaguar Health Inc (JAGX) reports increased revenue and strategic product launches, while navigating financial losses and regulatory hurdles.

GuruFocus.com 30 days ago

JAGX
-0.59%
Jaguar Health Reports Third Quarter 2024 Financial Results

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of ...

ACCESSWIRE 30 days ago

JAGX
-0.59%
Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

Click here to register for investor webcast Company plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 /Jaguar Health, Inc. (NASDAQ:JAGX) ...

ACCESSWIRE last month

JAGX
-0.59%
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based ...

ACCESSWIRE last month

JAGX
-0.59%
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based ...

ACCESSWIRE last month

JAGX
-0.59%
$Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting$

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2024 /Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the abstracts are ...

ACCESSWIRE last month

JAGX
-0.59%
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National ...

ACCESSWIRE last month

JAGX
-0.59%
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, CA / ACCESSWIRE / October 11, 2024 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 ...

ACCESSWIRE 2 months ago

JAGX
-0.59%
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional ...

ACCESSWIRE 2 months ago

JAGX
-0.59%

Performance Overview

Return	JAGX	S&P 500
YTD	-89.30%	+26.86%
1-Year	-90.44%	+30.31%
3-Year	-99.98%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Jaguar Health, Inc. (JAGX)

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Jaguar Health Reports Third Quarter 2024 Financial Results

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

Performance Overview